Soaring Eagle Acquisition said it intends to voluntarily withdraw its listing from the Nasdaq and move to the NYSE following completion of its pending business combination with Ginkgo Bioworks.
Ginkgo Bioworks Holdings is expected to begin trading on the NYSE the day after the closing of the business combination under DNA and DNA.WS. The SPAC’s shares and warrants will continue to trade on Nasdaq until the transfer is complete.
The decision to list on the NYSE was made in consideration of the business combination and enables the new enterprise “to be listed alongside other innovative companies that are also listed on the NYSE,” Soaring Eagle said in a press release. The NYSE listing and Nasdaq delisting are subject to the closing of the deal and fulfillment of all NYSE listing requirements.
The deal values the combined company at a $15 billion pre-money equity valuation. Led by former MGM CEO Harry Sloan, Soaring Eagle raised $1.5 billion in a February IPO. Read more.
